Literature DB >> 6762128

[Comparative effect of a single or continuous administration of "Saccharomyces boulardii" on the establishment of various strains of "candida" in the digestive tract of gnotobiotic mice].

R Ducluzeau, M Bensaada.   

Abstract

Saccharomyces boulardii became established in the digestive tract of monoxenic mice; the number of viable cells ranged around 10(7.5) per gram faeces. This yeast was drastically eliminated from the digestive tract of gnotoxenic mice harbouring a complex flora of human origin. In monoxenic mice harbouring S. boulardii, Candida albicans became established at a level equivalent to that observed in monoxenic mice harbouring C. albicans alone. If gnotoxenic mice received a concentrated suspension of viable S. boulardii cells so as to steadily maintain a population level close to 10(9) viable cells, C. albicans then became established at a level 10 to 50 times lower than that reached by the yeast strain alone. The antagonistic effect exerted in vivo by S. boulardii was preventive and curative. It was active against C. albicans, C. krusei and C. pseudotropicalis strains, but ineffective against C. tropicalis. This antagonistic effect disappeared when S. boulardii cells were killed by heating.

Entities:  

Mesh:

Year:  1982        PMID: 6762128

Source DB:  PubMed          Journal:  Ann Microbiol (Paris)        ISSN: 0300-5410


  14 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Use of artificial digestive systems to investigate the biopharmaceutical factors influencing the survival of probiotic yeast during gastrointestinal transit in humans.

Authors:  Stéphanie Blanquet-Diot; Sylvain Denis; Sandrine Chalancon; Fehd Chaira; Jean-Michel Cardot; Monique Alric
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

Review 3.  Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives.

Authors:  Jean-Paul Buts
Journal:  Dig Dis Sci       Date:  2008-06-05       Impact factor: 3.199

4.  Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition.

Authors:  Stephane-M Schneider; Fernand Girard-Pipau; Jerome Filippi; Xavier Hebuterne; Dominique Moyse; Gustavo-Calle Hinojosa; Anne Pompei; Patrick Rampal
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

5.  Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats.

Authors:  A V Boddy; G W Elmer; L V McFarland; R H Levy
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

6.  Studies on the time course of the effects of the probiotic yeast Saccharomyces boulardii on electrolyte transport in pig jejunum.

Authors:  B Schroeder; C Winckler; K Failing; G Breves
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

7.  Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters.

Authors:  G W Elmer; L V McFarland
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

8.  Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii.

Authors:  J P Buts; P Bernasconi; J P Vaerman; C Dive
Journal:  Dig Dis Sci       Date:  1990-02       Impact factor: 3.199

9.  Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii.

Authors:  R D Toothaker; G W Elmer
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Recombinant Saccharomyces cerevisiae strain expressing a model cytochrome P450 in the rat digestive environment: viability and bioconversion activity.

Authors:  G Garrait; J F Jarrige; S Blanquet; E Beyssac; M Alric
Journal:  Appl Environ Microbiol       Date:  2007-04-06       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.